Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
Insiders at Alzamend Neuro, Gain Therapeutics, Azitra, and Silo Pharma have recently made significant stock purchases. These transactions come amidst various developments within the companies, such as FDA approvals, executive appointments, financial results, and successful studies, indicating insider confidence in the companies' prospects.
April 02, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Azitra's CFO buys shares after announcing a FY23 loss, possibly indicating a belief in long-term recovery and value.
The CFO's purchase of Azitra shares following a loss announcement may indicate an insider belief in the company's potential for recovery and future value, despite short-term challenges.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Alzamend Neuro's director purchased shares following a 'Study May Proceed' letter from the FDA for a PTSD study, indicating potential growth.
The insider purchase at Alzamend Neuro following regulatory approval for a study suggests confidence in the company's future, potentially leading to positive investor sentiment and stock price growth.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Gain Therapeutics sees insider buying after naming a new chief medical officer, hinting at strategic growth and positive outlook.
The insider purchase at Gain Therapeutics coinciding with the appointment of a new chief medical officer suggests insider confidence in the company's strategic direction and potential for growth.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 85
POSITIVE IMPACT
Silo Pharma's CEO purchases shares after a successful PTSD therapeutic study, signaling confidence in the company's research and market potential.
The CEO's purchase of Silo Pharma shares after a successful study outcome suggests strong insider confidence in the company's research direction and potential market impact, likely to positively influence the stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90